Quest Diagnostics has finalized its acquisition of Haystack Oncology, a company specializing in minimal-residual disease testing using circulating tumor DNA. Quest plans to integrate this technology into new blood-based lab services for solid tumor cancers in 2024.
Quest Diagnostics (NYSE:DGX), the nation’s leading provider of diagnostic information services, today announced that it has completed its previously announced acquisition of Haystack Oncology.
Haystack Oncology has developed a highly sensitive minimal-residual disease (MRD) testing technology, based on circulating tumor DNA (ctDNA), to aid in the early detection of residual or recurring cancer and better inform therapy decisions. Quest expects to incorporate this MRD technology into the development of new blood-based clinical lab services for solid tumor cancers available beginning in 2024.
Source: BioSpace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.